SGEN is poised to become a major player in non hodgkin's (B-cell).
NHL is about a $6bil market now for Roche's frontline Rituxan with 100k new cases and about 600k living. Rituxan patents expire 2013-2018. Roche's breast cancer frontline drug Herceptin, (also about $6bil) patents expire 2014-2019. Both will soon be facing biosimular competition. Roche is in a race to keep those markets using frontline ADC's combine with Rituxan and Herceptin.
TDM 1, now approved, is a Herceptin ADC in collaboration with IMGN -which everyone knows.
SGEN will have 3 ADC's in development utilizing Rituzan.
In collaboration with Roche, now in Phase II there is an anti CD22 ADC+R(Rituxan) and anti CD76b+R. SGEN is slated to begin trials with Adcetris+R this year. I believe all three will produce better outcomes than current frontline regimes. While SGEN's share will not come close to the current $6bil enjoyed by Rituxan this represents at least a triple of the current HL-ALCL indication I'm my opinion.
I also believe SGEN will achieve it's added duration approval this year. Many who have achieved excellent results but have since relapsed will be wanting to continue treatments. This will be an immediate boast in Adcetris revenue. Again this is just my opinion.
While the current share price is high I will be buying any pull back.